Intravenous Iron Drugs Market to Grow at a Brisk Rate During Forecast Period

Increasing cases of renal disease and growing requirement of dialysis to drive global intravenous iron drugs through 2025

According to TechSci Research report, “Global Intravenous Iron Drugs Market By Application (Intestinal malabsorption syndromes, Inflammatory diseases, Gastrectomy/bariatric surgery, Anemia, Osier-Weber-Rendu disease, Angiodysplasia, Pregnancy, Others), By Product (Iron dextran, Ferric gluconate, Iron sucrose, Ferric carboxymaltos, Iron isomaltoside 1000, Ferumoxytol), By End-User (Hospitals, Clinics, Others), By Region, Forecast & Opportunities, 2025”, global market for intravenous iron drugs is expected to grow at a brisk rate throughout the forecast period. Iron is a major element in the composition of hemoglobin and helps in the transportation of oxygen in the entire body. Intravenous iron drugs are infused externally within the body with the help of needles to the patients who are unable to consume iron via oral drugs. These drugs are prescribed by doctors to anemic people or the ones who are deficient of iron. As per the survey conducted in 2017 by Vitamin and Mineral Nutrition Information System, 30% of anemia in children and women in developing countries is because of the deficiency of iron. Increasing anemic cases coupled with increasing patient pool undergoing dialysis are driving the growth of the market. Surging investments by governments and leading companies in the production and research on intravenous iron drugs is propelling the growth of the market.

Anemia is also prevalent in pregnant women which can be harmful for mothers as well as their unborn babies. Thus, intravenous iron drugs are indispensable to both, pregnant mothers and their babies. This is also one of the key factors leading to the growth of the market. There has been an evident rise in the awareness of people about chronic diseases such as anemia, bowel disease, etc., due to which they opt for intravenous iron drugs, thereby fueling the market growth. However, these drugs have some side effects which might impede the growth of the market.

Browse XX market data Tables and XX Figures spread through XXX Pages and an in-depth TOC on  “Global Intravenous Iron Drugs Market”

https://www.techsciresearch.com/report/intravenous-iron-drugs-market/5093.html

Global intravenous iron drugs market is segmented based on application, product, end-user, company and region. Based on product, the market is segregated into iron dextran, ferric gluconate, iron sucrose, ferric carboxymaltose, iron isomaltoside 1000 and ferumoxytol. Ferric carboxymaltose segment held the largest share in the market in the year 2019 because of its wide range of applications in the field of drug discovery. This FDA approved drug exhibits superior performance and is available at reduced costs. The end-user segment is divided into hospitals, clinics and others, out of which, clinics are expected to hold the largest share until 2025 as due to surge in the use of intravenous drugs at clinics. There are a lot of people undergoing dialysis lately, and clinics provide a platform for this purpose. They even administer iron dosages and ensure safe and reliable intravenous drug transmission.

Download Sample Report @ https://www.techsciresearch.com/sample-report.aspx?cid=5093

Customers can also request for 10% free customization on this report.

Some of the leading players in global intravenous iron drugs market include AMAG pharmaceuticals, Inc., Vifor Pharma Group, Daiichi Sankyo Company, Limited, Sanofi SA, Rockwell Medical Inc., Allergan PLC, Pfizer Inc, Nippon Shinyaku Co., Novartis International AG, Takeda Pharmaceutical Company Limited, Bausch Health Companies Inc., Shield Therapeutics PLC, Merck & Co., Inc. and Biocon Limited.

 “North America held the dominant position in 2019 in the global intravenous iron drugs market due to rising patient pool of anemia and various other diseases such as bowel disease. In addition to this, easy access to these drugs and advanced healthcare infrastructure is working in the favor of the market growth in the region. However, market in the Asia-Pacific region is expected to witness the maximum expansion during the forecast period as population in the emerging economies such as India and China is gradually becoming aware of the benefits of intravenous iron drugs.,” said Mr. Karan Chechi, Research Director with TechSci Research, a research based global management consulting firm.

“Global Intravenous Iron Drugs Market By Application (Intestinal malabsorption syndromes, Inflammatory diseases, Gastrectomy/bariatric surgery, Anemia, Osier-Weber-Rendu disease, Angiodysplasia, Pregnancy, Others), By Product (Iron dextran, Ferric gluconate, Iron sucrose, Ferric carboxymaltos, Iron isomaltoside 1000, Ferumoxytol), By End-User (Hospitals, Clinics, Others), By Region, Forecast & Opportunities, 2025”, has evaluated the future growth potential of global Intravenous iron drugs market and provided statistics & information on market size, shares, structure and future market growth. The report intends to provide cutting-edge market intelligence and help decision makers take sound investment decisions. Besides, the report also identifies and analyzes the emerging trends along with essential drivers, challenges and opportunities in global intravenous iron drugs market.

Contact

Mr. Ken Mathews

708 Third Avenue,

Manhattan, NY,

New York – 10017

Tel: +1-646-360-1656

Email: [email protected]